Statins for children with familial hypercholesterolemia

Area of Science:

• Pediatric Cardiology
• Metabolic Disorders
• Pharmacology

Background:

• Familial hypercholesterolemia (FH) is a common inherited disorder affecting at least 1 in 500 individuals worldwide.
• Early diagnosis and lifelong treatment are crucial due to premature atherosclerosis and cardiovascular disease risks.
• Current treatments include diet and, less commonly, anion exchange resins, with statins emerging as a focus since the 1990s.

Purpose of the Study:

• To evaluate the efficacy and safety of statin therapy in pediatric patients diagnosed with familial hypercholesterolemia.
• To synthesize evidence from randomized controlled trials comparing statins with placebo or diet alone in children.

Main Methods:

• Systematic review of randomized placebo-controlled studies involving participants up to 18 years old.
• Inclusion criteria focused on comparisons between statins and placebo or diet.
• Data extraction and study assessment performed independently by two authors.

Main Results:

• Eight randomized placebo-controlled studies with 1074 participants were included, with a median follow-up of 24 weeks.
• Statins significantly reduced LDL cholesterol levels across all time points without affecting liver enzymes or creatine kinase.
• Adverse events and myopathy risks were low and similar between statin and placebo groups; some studies indicated improvements in vascular function.

Conclusions:

• Statin therapy demonstrates significant lipid-lowering efficacy in children with familial hypercholesterolemia.
• Short-term safety appears favorable, with no major safety concerns identified.
• Long-term safety remains unestablished, necessitating careful pediatric monitoring and further large-scale, long-term randomized controlled trials.